Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.

Anthony D AndersonMohammed RajaNeisy VazquezMichele MorrisKrishna KomanduriJose Fernando Camargo

Published in: Clinical transplantation (2020)

This study confirms the efficacy of letermovir in preventing CMV reactivation in CMV R+ allogeneic HCT recipients in first 100 days post-HCT and suggests sustained efficacy after discontinuation of prophylaxis.

Keyphrases

stem cell transplantation
bone marrow
hematopoietic stem cell
single cell
high dose
cell therapy
mesenchymal stem cells